期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 14, 期 6, 页码 809-819出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2014.896335
关键词
antisense therapy; Duchenne muscular dystrophy; dysferlinopathy; exon skipping; Fukuyama congenital muscular dystrophy; limb-girdle muscular dystrophy 2B; Miyoshi myopathy; spinal muscular atrophy; splice modulation
资金
- University of Alberta Faculty of Medicine and Dentistry
- Parent Project Muscular Dystrophy (USA)
- Friends of Garrett Cumming Research Funds
- HM Toupin Neurological Science Research Funds
- Muscular Dystrophy Canada
- Canada Foundation for Innovation
- Alberta Enterprise
- Advanced Education
- Women and Children's Health Research Institute
- Canadian Institute of Health Research
Introduction: Antisense oligonucleotide (AON) therapy is a form of treatment for genetic or infectious diseases using small, synthetic DNA-like molecules called AONs. Recent advances in the development of AONs that show improved stability and increased sequence specificity have led to clinical trials for several neuromuscular diseases. Impressive preclinical and clinical data are published regarding the usage of AONs in exon-skipping and splice modulation strategies to increase dystrophin production in Duchenne muscular dystrophy (DMD) and survival of motor neuron (SMN) production in spinal muscular atrophy (SMA). Areas covered: In this review, we focus on the current progress and challenges of exon-skipping and splice modulation therapies. In addition, we discuss the recent failure of the Phase III clinical trials of exon 51 skipping (drisapersen) for DMD. Expert opinion: The main approach of AON therapy in DMD and SMA is to rescue ('knock up' or increase) target proteins through exon skipping or exon inclusion; conversely, most conventional antisense drugs are designed to knock down (inhibit) the target. Encouraging preclinical data using this 'knock up' approach are also reported to rescue dysferlinopathies, including limb-girdle muscular dystrophy type 2B, Miyoshi myopathy, distal myopathy with anterior tibial onset and Fukuyama congenital muscular dystrophy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据